This discussion combines the mechanistic insights into the inflammatory component in atherogenesis of Jon Laman with the clinical perspective of Wolfgang Koenig. They discuss how inflammation reseach may change CV treatment approaches in the future.
In the PEGASUS-TIMI 54 trial, ticagrelor on top of aspirin significantly reduced absolute risk of recurrent ischemic events, but increased the risk of TIMI major bleeding in DM patients with a history of MI.
Several animated discussions between young scientists and international leaders in cardiovascular medicine were recorded in the PACE-studio during ISA2015.
ISA2015 | Clinical Breakthroughs Dr. Eralp Bellibas shares pharmacokinetic and pharmacodynamic data of the apoA1-Milano-POPC (MDCO216), developed to mimic pre-beta HDL molecules, which was more potent at increasing cholesterol efflux in CAD patients than in healthy volunteers.
Prof. Ray defends the proposition 'Statins are enough for the prevention of CVD' and considers the opposing standpoint in the plenary 'Controversy session' entitled 'Statin therapy vs. novel interventions'. Ray thinks more CVD could be prevented if more people globally would have access to statins. Is it time to add statins to drinking water, then?
ISA 2015 Joost Besseling and colleagues developed a new prediction model to determine which patients might have a disease-causing FH mutation. The model works particularly well in young patients with familial hypercholesterolaemia.
ISA2015 | Clinical Breakthroughs Dr. Kontush shared data of a study into the lipidome of HDL particles. HDL particles with phosphatidylserine showed more cardioprotective properties, including antiinflammatory activity, than those without phospatidylserine, both in vitro and in mice.
ISA 2015 Prof. Peter Libby recapitulates evolving insights into the mechanism of acute coronary syndromes, and how we may be shifting from a predominance of plaque ruptures towards superficial erosion as the cause of ACS.
ISA2015 | Clinical Breakthroughs Dr. Bertrand Cariou presents data of a study that investigated the willingness of patients and physicians to use self-injections (either by prefilled pen or a prefilled syringe) to administer the PCSK9-antibody alirocumab.
ISA2015 | Clinical Breakthroughs Dr. Barton Duell presented efficacy and safety data of 4.5 years of treatment with mipomersen, showing sustained lowering of LDL-c, Lp(a) and apoB, without revealing new safety concerns.
ISA2015 | Clinical Breakthroughs Gisette Reyes-Soffer shares the findings on the effect of PCSK9-inhibitor alirocumab on VLDL, IDL, LDL and apoB-metabolism in healthy volunteers.
ISA2015 | Clinical Breakthroughs Harold Bays shares the results of treatment with a new potent chemical entity, cosabutate, hich safely modifies triglyceride and lipid fraction levels in patients with hypertriglyceridaemia.